bupivacaine(intraperitoneally) and ketamine (intravenously)
ApprovedSmall molecule
bupivacaine(intraperitoneally) and ketamine (intravenously) is one of 18 small molecule programs targeting Post Operative Pain. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Post Operative Pain
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Approved
Duragesic
CCephalon
Approved
Ketalar
AAultman Health Foundation
Approved
ESP Block With Bupivacaine
YYale University
Approved
Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Phase 3
bupivacaine(intraperitoneally) and ketamine (intravenously)
AAin Shams University
Approved
EXPAREL
Pacira Pharmaceuticals, IncPhase 1
TLC590
TTLC Biopharmaceuticals, Inc.
Phase 3
Voltaren
NovartisPreclinical
Oxycontin
PProtega
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAin Shams University